

Choroby serca u kobiet – perspektywa europejska

1. Economic burden of cardiovascular diseases in the enlarged European Union. Jose Leal i wsp. *Euro Heart J.* 2006;1610-1619
2. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Marco Stramba-Badiale i wsp. *Euro Heart J* 2006;27:994-1005
3. Gender-specific prescription for cardiovascular diseases? Marco Stramba-Badiale¹ and Silvia G. Priori *Euro Heart J* 2005;26,1571-1572
4. Women's Health at Heart, 7 March 2006, Brussels

Spoleczne uwarunkowania chorób serca u kobiet

1. Anson O., Paran E., Neumann L, Chernichovsky D. Gender differences in health perceptions and their predictors. *Soc. Sci. Med.* 1993, 36,4, 419-427
2. Aber S. Comparison inequalities in women's and men's health: Britain in the 1990. *Soc. Sci Med.* 1997;44,6, 773-787.
3. Aber S., Ginn J. Gender and inequalities in health in later life. *Soc. Sci Med.* 1999;36, 1,33-46.
4. Ben-Shlomo Y., Kuh D: A life course approach to chronic disease epidemiology, conceptual models, empirical challenges and interdisciplinary perspective. *International Journal of Epidemiology*, 2002, 31,285-293.
5. Blane D., Berney L., Montgomery SM, Domestic labour , paid employment and women's health: analysis of life course data. *Soc. Sci. Med.* 2001, 52,959-965.
6. Bute B.P., Mathew J., Blumenthal J.A., Welsh-Bohmer K., White W.D., Mark D., Landolfo K., Newman M.F. Female Gender is associated with impaired quality of life 1 year after coronary artery bypass surgery. *Psychosomatic Medicine* , 2003, 65,944-951.

7. Domański H. Nierówności płci w świadomości kobiet. *Promocja Zdrowia . Nauki Społeczne i Medycyna*, 1999, VI, 16,29-47.
8. Drygas W. Usprawnienie wczesnej diagnostyki i czynnej opieki nad osobami z ryzykiem rozwoju niedokrwiennej choroby serca. W: *Monitoring oczekiwanych efektów realizacji Narodowego Programu Zdrowia 1996-2005*. Red. Goryński P., Wojtyniak B., Kuszewski K. Ministerstwo Zdrowia PZH, Warszawa, 2005
9. Fenz W., Fogle B: Differences between male and female reactions to psychosocial and physical stressors: a review. *Society, stress, disease*. Oxford University Press, New York. Toronto, 1978.
10. Jaarsveld C.H.M. Sanderman R., Ranchor A.V. Ormel J., van Veldhuisen D.J. Kempen G.I.J.M: Gender specific changes in quality of life following cardiovascular disease: A prospective study. *J. Clin. Epidemiol* 2002, 55, 1105-1112
11. Macintyre S., Hunt K., Sweeting H. Gender differences in health: are things really as simply as they seem ? . *Soc. Sci. Med.* 1996, 42,4,617-624.
12. Ostrowska A. Płeć jako czynnik różnicowania zdrowia społeczeństwa. *Promocja Zdrowia. Nauki Społeczne i Medycyna*,1999,VI,16,48-67
13. Sobczak I. Starzenie się ludności w wieku produkcyjnym w Polsce. Liczba i struktura ludności w wieku produkcyjnym – mobilnym i niemobilnym. W: *Proces starzenia się ludności – potrzeby i wyzwania*. Red. Kowalewski J.T., Szukalski P. Łódź , 2002, 135-150.
14. Steptoe A., Lundwall K., Cropley M. Gender, family structure and cardiovascular activity during the working day and evening. *Soc. Sci. Med.* 2000, 50,3, 531.
15. Titkow A. Historyczno-społeczne uwarunkowania tożsamości kobiet w Polsce. *Promocja Zdrowia. Nauki Społeczne i Medycyna*, 1999, VI,16, 11-28.
16. Titkow A. Stres i życie społeczne. *Polskie doświadczenia*. PWN. Warszawa, 1993, 273-303 *Rocznik Statystyczny , GUS* 2004
17. Tobiasz- Adamczyk B. Cultural determinants of social position and health status of older women in Poland. w: *Gender, health, and cultures. Networking for better future for women within an enlarged Europe*. Ed. V. Lasch. W. Freitag. U. Sonntag. Kassel University Press, 2006 , 193-209.

18. Tobiasz- Adamczyk B., Brzyski P., Bajka J. Społeczne uwarunkowania jakości życia u progu wieku podeszłego. Uniwersytet Jagielloński 2004.
19. Verbrugge L.M. Gender health: an update on hypotheses and evidence. *J. of Health and Social Behaviour*, 1985, 26,156-182.
20. Warzywoda-Kruszyńska W. Rodzina w procesie przemian. W: Rodzina w zmieniającym się społeczeństwie polskim . Uniwersytet Łódzki, Łódź, 2004, 13-21.
21. Wojtyniak B. Oczekiwane korzyści zdrowotne realizacji Narodowego Programu Zdrowia.: Monitoring oczekiwanych efektów realizacji Narodowego Programu Zdrowia 1996-2005. Red. Goryński P, Wojtyniak B. Kuszewski K. Ministerstwo Zdrowia. PZH, Warszawa, 2005.
22. Wróblewska W. Women's health status in Poland in the transition to market economy. *Soc. Sci Med.* 2002,54.

Epidemiologia czynników ryzyka u polskich kobiet

1. Zdrojewski T., Bandosz P., Szpakowski P. i wsp.: Rozpowszechnienie głównych czynników ryzyka chorób układu sercowo-naczyniowego w Polsce. Wyniki badania NATPOL PLUS. *Kardiol. Pol.*, 2004,61 (supl. IV), IV-5- IV-26
2. Dane uzyskane od Autorów badania NATPOL PLUS
3. Rywik S., Broda G., Piotrowski W., Gaździk D. I wsp.: Wieloośrodkowe Ogólnopolskie Badanie Stanu Zdrowia Ludności Program WOBASZ. Stan zdrowia populacji polskiej w wieku 20-74 lata w okresie 2003-2005. Podstawowe wyniki badania przekrojowego. Próba ogólnopolska. Instytut Kardiologii im. Prymasa Tysiąclecia Stefana Kardynała Wyszyńskiego, Warszawa, 2005
4. Sekuła W., Figurska K., Jutrowska I. I wsp.: Changes in the food consumption pattern during the political and economic transition in Poland and their nutritional and health implications. *Pol. Popul. Rev.*, 2005, N 27, 141-158

Jak wyodrębnić wśród kobiet grupę o wysokim ryzyku chorób układu sercowo-naczyniowego?

1. De S, Searles G, Haddad H. The prevalence of cardiac risk factors in woman 45 years of age or younger undergoing angiography for evaluation of undiagnosed chest pain. *Can J Cardiol* 2002;18:945-948.
2. Unger R.H.: Lipid overload and overflow: metabolic trauma and the metabolic syndrome. *Trends Endocrinol Metab*, 2003; 14:398-403
3. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. *Am J Cardiol* 2000;86:943-949.
4. Couillard, Bergeron N, Prud'homme D, et al. Gender difference in postprandial lipemia : importance of visceral adipose tissue accumulation. *Arterioscler Thromb Vasc Biol* 19:2448-2455.
5. Stranges S, Trevisan M, Dorn J. M, Dmochowski J, Donahue R. P. Body Fat Distribution, Liver Enzymes, and Risk of Hypertension. *Hypertension*. 2005; 46:1186-1193.

Nadciśnienie tętnicze u kobiet

- problem wciąż niedoceniany

1. Broda G. Choroby Układu krążenia w Polsce – umieralność. Dostępne w <http://www.kardiolog.pl/mod/archiwum/4779.html>
2. [Daly CA](#), [Clemens F](#), [Sendon JL](#), [Tavazzi L](#), [Boersma E](#), [Danchin N](#), [Delahaye F](#), [Gitt A](#), [Julian D](#), [Mulcahy D](#), [Ruzyllo W](#), [Thygesen K](#), [Verheugt F](#), [Fox KM](#); [Euro Heart Survey Investigators](#). The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina. *Eur Heart J*. 2005; 26: 996-1010.
3. Klocek M, [Kawecka-Jaszcz K](#). Quality of life in patients with essential arterial hypertension. Part I and II: The effect o socio-demographic factors. *Przegl Lek*. 2003; 60: 92 -106.

4. Kornacewicz-Jach Z, Kossuth I, Czechowska M. Jak rozpoznać chorobę wieńcową u kobiet? *Kardiol Pol* 2005; 62: 294-298.
5. Tobiasz-Adamczyk B, Bajka J, Brzyski P. Społeczne uwarunkowania jakości życia kobiet u progu wieku starszego. *Badania porównawcze*. Wydawnictwo Uniwersytetu Jagiellońskiego 2004.
6. Tykarski A, Posadzy-Mańczyńska A, Wyrzykowski B, Kwaśniewska M, Pająk A, Tendera M, Rywik S, Broda G, Zdrojewski T. Rozpowszechnienie nadciśnienia tętniczego oraz skuteczność jego leczenia u dorosłych mieszkańców naszego kraju. Wyniki programu WOBASZ. *Kardiol Pol* 2005; 63; S614-S619.

Cukrzyca a ryzyko sercowo-naczyniowe u kobiet

1. Gu K., Cowie C.C., Harris M.J.: Diabetes and decline in heart disease mortality in US adults. *JAMA*, 1999, 281, 1291-7
2. Escobar-Morreale H.N., Villuendas G., Botella-Carretero J.I. I wsp.: Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in premenopausal women. *Diabetologia*, 2003, 46, 625-33
3. Ridker P.M., Buring J.E., Cook N.R. i wsp.: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. *Circulation*, 2003, 107, 391-7
4. Pan X.R., Yang W.Y., Li G.W. I wsp.: Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. *Diabetes Care*, 1997, 20, 1664-9
5. Hu F.B., Manson J.E., Stampfer M.J. I wsp.: Diet, lifestyle, and risk of type 2 diabetes mellitus in women. *NEJM*, 2001, 345, 790-7
6. Hillier T.A., Pedula K.L.: Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. *Diabetes Care* 2001, 24, 1522-7
7. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. *European Epidemiology*

- Study Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. *Lancet* 1999, 354, 617-21.
8. de Vegt F., Dekker J.M., Ruhe H.G. i wsp.: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. *Diabetologia*, 1999, 42, 926-31
 9. Katzmarzyk P.T., Tremblay A., Petusse L.I. i wsp.: The utility of international child and adolescent overweight guidelines for predicting coronary heart disease risk factors. *J.Clin.Epidemiol.* 2003, 56, 456-62
 10. Ceriello A., Motz F.: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common hypothesis revisited. *Atheroscler. Thromb.Vasc.Biol.* 2004, 24, 816-23.
 11. Agatston A.S.: The end of diet debates? All fats and carbs are not created equal. *Cliv.Clin.J.Med.* 2005, 72, 976-83
 12. Holt R.: The new subspeciality of metabolic medicine. *Diabetes Obes.Metab.* 2003, 5, 356-57
 13. Calsson S., Hammar N., Grill V. I wsp.: Alcohol consumption and the incidence of type 2 diabetes: 20-year follow-up of the Finish Twin Cohord Study. *Diabetes Care*, 2003, 26, 2785-90
 14. Bandurska – Stankiewicz E., Kołakowska H., Żbikowska E.: Zapadalność na inwalidztwo wzroku z powodu cukrzycy w województwie olsztyńskim w latach 1990-999. *Pol.Arch.Med.Wewn.* 2001, 106, 839-45

Udar mózgu u kobiet

1. Bousser M-G. Stroke in women. *Circulation* 1999, 99, 463-7
2. Bushnell Ch, Griffin J, Newby K i wsp. Statin use and sex- specific stroke outcomes in patients with vascular disease. *Stroke*, 37, 1427-31
3. Członkowska A, Kobayashi A. Udary mózgu u starszych kobiet- czynniki ryzyka i rokowanie. *Kosmos- problemy nauk biologicznych.* 2003. 52, 77-82
4. Muller-Nordhorn J, Nolte CH, Rosnagel K i wsp. Medical management in patients following stroke and transitory ischemic attack: a comparison between men and women. *Cerebrovasc. Dis.* 2006, 21, 329-35

5. Niewada M, Kobayashi A, Sandercock PAG, Kaminski B, Członkowska A. Influence of gender on baseline features and clinical outcomes among 17,370 patients with confirmed ischaemic stroke in the International Stroke Trial. *Neuroepidemiology* 2005, 24, 123-8
6. Ridker PM, Cook NR, Lee I-M i wsp. A randomized trial of low- dose aspirin in the primary prevention of cardiovascular disease in women. *New Engl J Med.* 2005, 352, 1293-1304
7. Wiszniewska M, Kobayashi A, Milewska D, Szych Z, Członkowska A. Różnice pomiędzy czynnikami ryzyka u mężczyzn i kobiet z udarem niedokrwoennym mózgu w różnym wieku. *Postępy Psychiatrii i Neurologii* 2006, 15, 7-10
8. Wiszniewska M, Kobayashi A, Milewska D, Szych Z, Członkowska A. Czy przebieg oraz następstwa udaru niedokrwoennego mózgu są różne u kobiet i mężczyzn w zależności od wieku?. *Postępy Psychiatrii i Neurologii* 2006, 15, 11-15

Odrębności diagnostyki choroby wieńcowej u kobiet

1. Reunanen A, Suhonen O, Aromaa A, Knekt P, Pyörala K. Incidence of different manifestations of coronary heart disease in middle-aged Finnish men and women. *Acta Med Scand* 1985, 218, 19-26
2. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. *Am Heart J* 1986, 111, 383-390
3. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary artery disease. *N Engl J Med*, 1979, 300, 1350-1358.
4. Chaitman BR, Bourassa MG, Davis K, Rogers WJ, Tyras DH, Berger R i wsp. Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS). *Circulation* 1981, 64, 360-367
5. Lewandowski M, Szwed H, Kowalik I, Sadowski Z, Gąsior Z, Gackowski A i wsp. Wartość diagnostyczna spoczynkowego badania elektrokardiograficznego w rozpoznawaniu stabilnej choroby wieńcowej. *Pol Arch Med Wew*, 1999, 101, 403-411.

6. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Flether GF, Froelicher VF i wsp. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2002;40:1531-1540
7. Osbakken MD, Okada RD, Boucher CA, Strauss HW, Pohost GM. Comparison of exercise perfusion and ventricular function imaging: an analysis of factors affecting the diagnostic accuracy of each technique. *J Am Coll Cardiol* 1984, 3, 272-283
8. Guidelines of the management of stable angina pectoris: executive summary. The task force of the management of stable angina pectoris of the European Society of Cardiology. *Europ Heart J* 2006, 27,1341-1381
9. Alexander KP, Shaw LJ, DeLong ER, Mark DB, Peterson ED. Value of exercise treadmill testing in women. *J Am Coll Cardiol*, 1998, 32, 1657-1664

Leczenie interwencyjne choroby niedokrwiennej serca u kobiet

1. Stramba-Badiale M., Priori SG., Collins P., et al.: Cardiovascular diseases in woman: a statement from the policy conference of the European Society of Cardiology. *Eur. Heart Journal* 2006;27:994-1005
2. Dwyer BK., Taylor L., Fuller A., et al.: Percutaneous transluminal coronary angioplasty and stent placement in pregnancy. *Obstet Gynecol* 2005; 106: 1162-1164
3. James AH., Jamison MG., Biswas MS., et al.: Acute myocardial infarction in pregnancy. A United States population – based study. *Circulation* 2006;113:1564-1571.
4. Lansky AJ., Pietras C., Costa RA., et al.: Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (**CADILLAC**) Trial. *Circulation* 2005;111:1611-1618
5. 2006 Heart and Stroke Statistics For Women American Heart Association Heart Disease and Stroke Statistics — 2006 Update.
<http://www.americanheart.org/presenter.jhtml?identifier=3037185>

6. Lansky AJ., Hochman JS., Ward PA., et al.: Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women A Statement for Healthcare Professionals From the American Heart Association (Circulation. 2005;111:940-953.)
7. Jacobs AK.: Women, Ischemic Heart Disease, Revascularization, and the Gender Gap What Are We Missing? JACC, 2006;47:63S-65S
8. Ardissino D., Cavallini C., Bramucci E., et al.: Sirolimus-Eluting vs Uncoated Stents for Prevention of Restenosis in Small Coronary Arteries: A Randomized Trial. JAMA. 2004 292:2727-2734.
9. Chauhan MS., Ho KKL., Baim DS., et al.: Effect of gender on in-hospital and one-year outcomes after contemporary coronary artery stenting. Am J Cardiol. 2005;95:101-104.

Operacje pomostowania tętnic wieńcowych u kobiet

1. Mickleborough L.L., Tagaki Y., Maruyama H. i wsp.: Is sex a factor in determining operative risk for aortocoronary bypass graft surgery? Circulation 1995; 92 (supl. II): 80–84.
2. Koch C.G., Khandwala F., Nussmeier N., Blackstone E.H.: Gender and outcomes after coronary artery bypass grafting: a propensity-matched comparison. J. Thorac. Cardiovasc. Surg. 2003; 126; 2032–2043.
3. Blankstein R., Ward R.P., Arnsdorf M. i wsp.: Female gender is an independent predictor of operative mortality after coronary artery bypass graft surgery: contemporary analysis of 31 midwestern hospitals. Circulation 2005; 112: I323–I327.
4. Nussmeier N.A.: Are women different from men in ways that matter? Maybe. J. Thorac. Cardiovasc. Surg. 2006; 131: 264–265.
5. Toumpoulis I.K., Anagnostopoulos C.E., Balaram S.K. i wsp.: Assessment of independent predictors for long-term mortality between women and men after coronary artery bypass grafting: Are women different from men? J. Thorac. Cardiovasc. Surg. 2006; 131: 343–351.

Hormonalna terapia zastępcza a ryzyko chorób układu krążenia - Punkt widzenia kardiologa

1. Grodstein F., Stampfer M.J., Manson J.E. i wsp.: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. *N. Engl. J. Med.* 1996; 335: 453–461.
2. Hulley S., Grady D., Bush T. i wsp.: Randomized trials of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA* 1998; 280: 605–613.
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2005; 288: 321–233.
4. The Women's Health initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 2004; 291: 1701-1712.
5. Hodis H.N., Mack W.J., Lobo R.A. i wsp., the Estrogen in the Prevention Atherosclerosis Trial Research Group: Estrogen in the Prevention of Atherosclerosis. A randomized, double-blind, placebo-controlled trial. *Ann. Intern. Med.* 2001; 135: 939–953.
6. Mosca L., Appel L.J., Benjamin E.J. i wsp.: Evidence-based guidelines for cardiovascular disease prevention in women. *Circulation* 2004; 109: 672–693.
7. Raggi P., Callister T.Q., Cooil B. i wsp.: Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. *Circulation* 2000; 1001: 850–855.
8. Lobo R.A.: Evaluation of cardiovascular events rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. *Arch. Intern. Med.* 2004; 164: 482–484.
9. Byington R.P., Furberg C.D., Herrington D.M. i wsp.: Effects of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. *Atheroscler. Thromb. Vasc. Biol.* 2005; 22: 1692–1697.
10. Clarkson T.B.: Progestogens and cardiovascular disease. A critical review. *J. Reprod. Med.* 1999; 44: 180–184.

11. Reuben D.B., Palla S.L., Hu P. i wsp.: Progesterin affects mechanism of estrogen-induced C-reactive protein stimulation. *Am. J. Med.* 2006; 119: 167.e1–167.e8

Hormonalna terapia zastępcza a ryzyko chorób układu krążenia - Punkt widzenia ginekologa

1. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of Oral and Transdermal Estrogen Replacement Therapy on Markers of Coagulation, Fibrinolysis, Inflammation and Serum Lipids and Lipoproteins in Postmenopausal Women. *Thromb Haemost* 2001; 85: 619-25.
2. Hoibraaten E, Qvigstad E, Andersen TO, et al. The Effect of Hormone Replacement Therapy (HRT) on Hemostatic Variables in Women with Previous Venous Thromboembolism - Results from a Randomized, Double-Blind, Clinical Trial. *Thromb Haemost* 2001; 85: 775-81.
3. Stachowiak G, Połać I, Stefańczyk L, Jędrzejczyk S, Pertyński T. Increased risk of venous thromboembolism during estrogen-progesterin hormone replacement therapy in lower limb varicose vein women. *Sing J Obstet Gynaecol* 2003; 34: 27-33.
4. Daly E, Vessey MP, Hawking MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. *Lancet* 1996; 348: 977-80.
5. Grodstein F, Manson JE, Stanpfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. *J Womens Health* 2006; 15: 35-44.
6. van Baal WM, Emeis JJ, Kenemans P, et al. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. *Eur J Clin Invest* 1999; 29: 913-21.
7. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/Progesterin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progesterin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA* 1998; 280: 605-13.
8. Larkin M. Ups and downs for HRT and heart disease. *Lancet* 2000; 355: 1338.

Problemy psychologiczne u kobiet w okresie okołomenopauzalnym

1. Z. Lew-Starowicz, Encyklopedia Erotyki, MUZA, Warszawa 2000.
2. Z. Lew-Starowicz, Zaburzenia seksualne w praktyce ogólnolekarskiej, TerMedia, Poznań 2004
3. Z. Lew-Starowicz, *Seksualność a jakość życia człowieka*, „Przegląd Seksuologiczny” 2006, II, 1, 5, 21-26.
4. Z. Lew-Starowicz, *Seksualność Polek*, „Przegląd Seksuologiczny” 2005, I, 4, 4, 19-23.